Turmeric Acquisition Corp. (NASDAQ:TMPM) announced this morning that it has opted to liquidate its trust, dispersing approximately $10.05 per share to holders.
The SPAC’s shares will cease trading as of the open on October 20. Turmeric will hold on to up to $100,000 of accrued interest to pay for dissolution expenses.
Turmeric originally raised $97.8 million in its October 2020 IPO and endeavored to combine with an “off-the-radar” life sciences company with promising drug candidates for oncology or rare diseases. This has been a particularly tricky field for SPACs seeking to achieve near-term returns in recent years.
Of the 33 drug discovery or development biotech companies that have completed SPAC transactions dating back to May 2019, only one closed Friday above $10 – Immatics Biotechnologies (NASDAQ:IMTX). It completed its combination with ARYA Sciences I in June 2020.
Turmeric becomes the 35th SPAC to announce its intention to liquidate in 2022, 28 of which have already completed their liquidations.
Globa Terra Acquisition Corporation (NASDAQ:GTERU) announced the pricing of its $152 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “GTERU”, Wednesday, July 9, 2025. The new SPAC plans to mount a search for a target in the agriculture, agtech or biotech sectors with an emphasis on water...
M3-Brigade V (NASDAQ:MBAV) has entered into a definitive agreement to combine with crypto treasury firm ReserveOne, assembling about $1 billion in equity funding. ReserveOne is setting up a diversified Bitcoin and digital asset treasury with a portion of its investments going towards blockchain infrastructure and venture raises. The combined company is expected to trade on...
At the SPAC of Dawn As the SPAC market has warmed in 2025, only 21 of the 70 SPACs (30%) that have IPO’d thus far have overfunded their trusts to draw in investors and none of these funded to more than 101%. By contrast, 87% of 2023 SPACs were overfunded – some to as high...
Emmis Acquisition Corporation (NASDAQ:EMISU) has filed for a $100 million SPAC to take a look at the manufacturing sector after a few unique wrinkles in their IPO process. Initial investors are set to receive one right to a 1/10 share in each unit purchased and the SPAC will have 18 months to complete a business...
Chenghe III (NASDAQ:CHEC.U) has filed for a $110 million SPAC to continue the team’s growing series while turning to a new underwriter. The new SPAC is offering investors a 1/2 warrant in each unit and no overfunding of the trust, but it will need to complete a business combination within 18 months of its IPO...